1: Yoshida J, Abe H, Watanabe T, Kawada M. Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells. Oncol Lett. 2018 Nov;16(5):6777-6785. doi: 10.3892/ol.2018.9485. Epub 2018 Sep 21. PubMed PMID: 30405822; PubMed Central PMCID: PMC6202497.
2: Ohishi T, Masuda T, Abe H, Hayashi C, Adachi H, Ohba SI, Igarashi M, Watanabe T, Mimuro H, Amalia E, Inaoka DK, Mochizuki K, Kita K, Shibasaki M, Kawada M. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter. 2018 Apr;23(2):e12470. doi: 10.1111/hel.12470. Epub 2018 Feb 28. PubMed PMID: 29488678.
3: Abe H, Kawada M, Igarashi M, Ohba SI, Hayashi C, Sakashita C, Watanabe T, Shibasaki M. Biological activity of intervenolin analogs with a phenyl substituent. J Antibiot (Tokyo). 2017 Oct 11. doi: 10.1038/ja.2017.123. [Epub ahead of print] PubMed PMID: 29018268.
4: Kawada M, Inoue H, Ohba S, Hatano M, Amemiya M, Hayashi C, Usami I, Abe H, Watanabe T, Kinoshita N, Igarashi M, Masuda T, Ikeda D, Nomoto A. Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2. J Antibiot (Tokyo). 2013 Sep;66(9):543-8. doi: 10.1038/ja.2013.42. Epub 2013 May 1. PubMed PMID: 23632919.
5: Abe H, Kawada M, Inoue H, Ohba S, Nomoto A, Watanabe T, Shibasaki M. Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents. Org Lett. 2013 May 3;15(9):2124-7. doi: 10.1021/ol400587a. Epub 2013 Apr 17. PubMed PMID: 23594173.